Carbon monoxide releasing molecule-2 increases fibrinogen-dependent coagulation kinetics but does not enhance prothrombin activity

被引:19
作者
Nielsen, Vance G. [1 ]
Malayaman, S. Nini [1 ]
Khan, Ejaz S. [1 ]
Kirklin, James K. [2 ]
George, James F. [2 ]
机构
[1] Drexel Univ, Coll Med, Dept Anesthesiol, Philadelphia, PA 19102 USA
[2] Univ Alabama, Dept Surg, Birmingham, AL 35294 USA
关键词
carbon monoxide releasing molecule; fibrinogen; prothrombin; thrombelastography; DEFICIENT PLASMAS; THROMBUS GROWTH; FACTOR-VII; STRENGTH; VELOCITY;
D O I
10.1097/MBC.0b013e328338948f
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
We have previously determined that tricarbonyldichlororuthenium (II) dimer (CORM-2) increases plasma clot velocity of formation and strength by enhancing thrombin-fibrinogen interactions as determined by thrombelastography. The purpose of the present investigation was to further define the nature of CORM-2 interaction with prothrombin and fibrinogen by exposing purified proteins to CORM-2 or generating protein concentration-response curves in the absence or presence of CORM-2. Purified prothrombin was exposed to 0 or 100 mu mol/l CORM-2 prior to being added to prothrombin-deficient plasma (n=7-8 per condition). Fibrinogen-deficient plasma had fibrinogen added for a final concentration of 100-800 mg/dl and was exposed to 0 or 100 mu mol/l CORM-2 (n=4 per condition). Following tissue factor activation, thrombelastographic data were collected until clot strength stabilized. Exposure of prothrombin to CORM-2 did not significantly enhance coagulation kinetics. In sharp contrast, CORM-2 exposure enhanced fibrinogen coagulation kinetics in a concentration-dependent fashion, with peak effect seen at a fibrinogen concentration of 300 mg/dl that then progressively decreased throughout the range tested. Our data demonstrate that CORM-2 does not enhance plasma coagulation kinetics by modifying prothrombin; instead, the concept that CORM-2 modifies fibrinogen is the most likely explanation for the enhanced thrombin-fibrinogen interactions observed. Blood Coagul Fibrinolysis 21:349-353 (C) 2010 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins.
引用
收藏
页码:349 / 353
页数:5
相关论文
共 6 条
[1]   Therapeutic applications of carbon monoxide-releasing molecules [J].
Motterlini, R ;
Mann, BE ;
Foresti, R .
EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2005, 14 (11) :1305-1318
[2]   Carbon monoxide releasing molecule-2 decreases thick diameter fibrin fibre formation in normal and factor XIII deficient plasmas [J].
Nielsen, Vance G. ;
Kirklin, James K. ;
George, James F. ;
Messinger, Jeffrey D. .
BLOOD COAGULATION & FIBRINOLYSIS, 2010, 21 (01) :101-105
[3]   Carbon monoxide releasing molecule-2 increases the velocity of thrombus growth and strength in hemophilia A, hemophilia B and factor VII-deficient plasmas [J].
Nielsen, Vance G. ;
Kirklin, James K. ;
George, James F. .
BLOOD COAGULATION & FIBRINOLYSIS, 2010, 21 (01) :41-45
[4]   Carbon monoxide-releasing molecule-2 decreases fibrinolysis in human plasma [J].
Nielsen, Vance G. ;
Kirklin, James K. ;
George, James F. .
BLOOD COAGULATION & FIBRINOLYSIS, 2009, 20 (06) :448-455
[5]   Carbon monoxide releasing molecule-2 increases the velocity of thrombus growth and strength in human plasma [J].
Nielsen, Vance G. ;
Kirklin, James K. ;
George, James F. .
BLOOD COAGULATION & FIBRINOLYSIS, 2009, 20 (05) :377-380
[6]   Effects of coagulation factor deficiency on plasma coagulation kinetics determined via thrombelastography®:: critical roles of fibrinogen and factors II, VII, X and XII [J].
Nielsen, VG ;
Cohen, BM ;
Cohen, E .
ACTA ANAESTHESIOLOGICA SCANDINAVICA, 2005, 49 (02) :222-231